191 related articles for article (PubMed ID: 36701935)
1. The cost of opioid use disorder-related conditions in Medicare.
Mark TL; Parish WJ; Weber EM; Steinberg DG; Henretty K
Drug Alcohol Depend; 2023 Mar; 244():109778. PubMed ID: 36701935
[TBL] [Abstract][Full Text] [Related]
2. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
[TBL] [Abstract][Full Text] [Related]
3. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
4. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
6. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
[TBL] [Abstract][Full Text] [Related]
7. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
[TBL] [Abstract][Full Text] [Related]
8. Total cost of care associated with opioid use disorder treatment.
Toseef MU; Durfee J; Podewils LJ; Blum J; McEwen D; Hanratty R; Everhart R
Prev Med; 2023 Jan; 166():107345. PubMed ID: 36370891
[TBL] [Abstract][Full Text] [Related]
9. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
10. Quality of Opioid Use Disorder Treatment for Persons With and Without Disabling Conditions.
Thomas CP; Stewart MT; Ledingham E; Adams RS; Panas L; Reif S
JAMA Netw Open; 2023 Mar; 6(3):e232052. PubMed ID: 36884250
[TBL] [Abstract][Full Text] [Related]
11. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019".
Krawczyk N; Rivera BD; Jent V; Keyes KM; Jones CM; Cerdá M
Int J Drug Policy; 2022 Dec; 110():103786. PubMed ID: 35934583
[TBL] [Abstract][Full Text] [Related]
12. Outpatient follow-up and use of medications for opioid use disorder after residential treatment among Medicaid enrollees in 10 states.
; Cole ES; Allen L; Austin A; Barnes A; Chang CH; Clark S; Crane D; Cunningham P; Fry CE; Gordon AJ; Hammerslag L; Idala D; Kennedy S; Kim JY; Krishnan S; Lanier P; Mahakalanda S; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Tang L; Zivin K; Donohue JM
Drug Alcohol Depend; 2022 Dec; 241():109670. PubMed ID: 36332591
[TBL] [Abstract][Full Text] [Related]
13. Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings.
Peterson L; Murugesan M; Nocon R; Hoang H; Bolton J; Laiteerapong N; Pollack H; Marsh J
PLoS One; 2022; 17(10):e0276066. PubMed ID: 36256662
[TBL] [Abstract][Full Text] [Related]
14. Utilization of treatment by Medicaid enrollees with opioid use disorder and co-occurring substance use disorders.
O'Brien P; Henke RM; Schaefer MB; Lin J; Creedon TB
Drug Alcohol Depend; 2020 Dec; 217():108261. PubMed ID: 32979735
[TBL] [Abstract][Full Text] [Related]
15. Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort.
McCann NC; LaRochelle MR; Morgan JR
J Subst Use Addict Treat; 2024 Apr; 159():209281. PubMed ID: 38122988
[TBL] [Abstract][Full Text] [Related]
16. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
[TBL] [Abstract][Full Text] [Related]
17. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.
Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC
J Subst Use Addict Treat; 2024 Feb; 157():209271. PubMed ID: 38135120
[TBL] [Abstract][Full Text] [Related]
18. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
19. Users of retail medications for opioid use disorders faced high out-of-pocket prescription spending in 2011-2017.
McClellan C; Moriya A; Simon K
J Subst Abuse Treat; 2022 Jan; 132():108645. PubMed ID: 34728135
[TBL] [Abstract][Full Text] [Related]
20. Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.
Hollander MAG; Chang CH; Douaihy AB; Hulsey E; Donohue JM
Drug Alcohol Depend; 2021 Oct; 227():108927. PubMed ID: 34358766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
